TGFB1 and neoplasm: TGF-β stimulation increases FGFR2c levels, enhancing sensitivity to fibroblast growth factor 2 and promoting EMT, suggesting that inhibiting TGF-β signaling could mitigate tumor bone metastases through AS modulation [269].